Analysts Anticipate Bicycle Therapeutics plc (NASDAQ:BCYC) Will Announce Earnings of -$0.70 Per Share

Equities research analysts expect Bicycle Therapeutics plc (NASDAQ:BCYCGet Rating) to post ($0.70) earnings per share for the current quarter, Zacks reports. Seven analysts have made estimates for Bicycle Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.79) and the highest estimate coming in at ($0.64). Bicycle Therapeutics reported earnings per share of ($0.73) in the same quarter last year, which would suggest a positive year over year growth rate of 4.1%. The company is scheduled to report its next quarterly earnings report on Monday, January 1st.

According to Zacks, analysts expect that Bicycle Therapeutics will report full year earnings of ($3.05) per share for the current financial year, with EPS estimates ranging from ($4.17) to ($2.52). For the next year, analysts forecast that the firm will post earnings of ($3.85) per share, with EPS estimates ranging from ($5.00) to ($2.99). Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side analysts that cover Bicycle Therapeutics.

Bicycle Therapeutics (NASDAQ:BCYCGet Rating) last announced its quarterly earnings data on Tuesday, March 1st. The company reported ($0.63) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.60) by ($0.03). Bicycle Therapeutics had a negative return on equity of 33.36% and a negative net margin of 571.25%. The firm had revenue of $3.77 million for the quarter, compared to analyst estimates of $6.31 million.

Several analysts recently commented on the company. JMP Securities decreased their price target on Bicycle Therapeutics from $85.00 to $70.00 and set a “market outperform” rating on the stock in a research note on Thursday, March 3rd. Morgan Stanley assumed coverage on Bicycle Therapeutics in a research note on Monday, February 14th. They issued an “equal weight” rating and a $60.00 price target on the stock. SVB Leerink assumed coverage on Bicycle Therapeutics in a research note on Friday, December 17th. They issued an “outperform” rating and a $70.00 price target on the stock. Zacks Investment Research lowered Bicycle Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, January 10th. Finally, Cantor Fitzgerald began coverage on Bicycle Therapeutics in a research report on Thursday. They issued an “overweight” rating and a $80.00 price objective for the company. Two equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $68.33.

Shares of NASDAQ:BCYC traded down $16.12 during trading on Wednesday, hitting $30.87. 114,479 shares of the stock were exchanged, compared to its average volume of 289,350. The company’s fifty day simple moving average is $44.99 and its 200-day simple moving average is $50.26. The company has a debt-to-equity ratio of 0.09, a quick ratio of 12.65 and a current ratio of 12.65. The company has a market capitalization of $913.72 million and a price-to-earnings ratio of -11.69. Bicycle Therapeutics has a 1-year low of $26.39 and a 1-year high of $62.08.

A number of large investors have recently added to or reduced their stakes in the business. Shilanski & Associates Inc. bought a new position in shares of Bicycle Therapeutics during the fourth quarter worth approximately $314,000. Personal CFO Solutions LLC increased its stake in shares of Bicycle Therapeutics by 3.7% during the third quarter. Personal CFO Solutions LLC now owns 7,558 shares of the company’s stock worth $314,000 after purchasing an additional 273 shares during the period. HighMark Wealth Management LLC increased its stake in shares of Bicycle Therapeutics by 590.9% during the fourth quarter. HighMark Wealth Management LLC now owns 4,325 shares of the company’s stock worth $263,000 after purchasing an additional 3,699 shares during the period. State of New Jersey Common Pension Fund D bought a new position in shares of Bicycle Therapeutics during the third quarter worth approximately $203,000. Finally, Jump Financial LLC bought a new position in shares of Bicycle Therapeutics during the third quarter worth approximately $715,000. Hedge funds and other institutional investors own 54.69% of the company’s stock.

About Bicycle Therapeutics (Get Rating)

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease.

Recommended Stories

Get a free copy of the Zacks research report on Bicycle Therapeutics (BCYC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Bicycle Therapeutics (NASDAQ:BCYC)

Receive News & Ratings for Bicycle Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bicycle Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.